Profile
Antony Blanc worked as the Chief Business Officer at Synosia Therapeutics AG from 2000 to 2009.
He also held the position of Head-Biopharma at Syngenta AG during the same period.
Prior to that, he was an Associate Partner at Mckinsey & Co., Inc. (Germany) from 1994 to 2017.
Currently, he is serving as the Chief Business & Commercial Officer at CureVac NV, a position he started in 2020 and will continue until 2023.
Dr. Blanc obtained his undergraduate and doctorate degrees from McGill University.
Former positions of Antony Blanc
| Companies | Position | End |
|---|---|---|
| CUREVAC N.V. | Corporate Officer/Principal | 2023-11-30 |
| Mckinsey & Co., Inc. (Germany) | Corporate Officer/Principal | 2016-12-31 |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Corporate Officer/Principal | 2008-12-31 |
| SYNGENTA | Corporate Officer/Principal | 2008-12-31 |
Training of Antony Blanc
| McGill University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CUREVAC N.V. | Health Technology |
| Private companies | 3 |
|---|---|
| Mckinsey & Co., Inc. (Germany) | |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Syngenta AG
 Syngenta AG Chemicals: AgriculturalProcess Industries Syngenta AG specializes in crop protection and seeds production. Its products include selective and non-selective herbicides, fungicides, insecticides, as well as field crop and vegetable seeds. The company was founded on November 12, 1999 and is headquartered in Basel, Switzerland. | Process Industries |
- Stock Market
- Insiders
- Antony Blanc
